Stonebridge’s first fund invests more than half of committed capital Fund deploys capital across sectors including biotech, technology, logistics and food
Translated by Ryu Ho-joung 공개 2021-09-23 07:37:42
이 기사는 2021년 09월 23일 07:31 thebell 에 표출된 기사입니다.
Seoul-based private equity firm Stonebridge Capital’s first bind-pool fund has deployed more than half of its committed capital, only about a year after the fund began investing.Stonebridge Mid Cap I, which closed in July 2020 with 306 billion won ($260 million) in commitments, has invested roughly 187 billion won to date, which represents about 60% of its committed capital.
The ratio of invested capital to committed capital is likely to increase to 75% before the end of the year when considering two more deals in the pipeline.
Most recently the private equity firm signed a deal to acquire nutritional supplement company Health balance for 80 billion won in partnership with Daehan Flour Mill, with about 50 billion won of the acquisition cost set to be financed through the fund. The deal is expected to close next month.
The fund’s other portfolio companies include Texas-based Caris Life Sciences and Cloocus, a cloud managed service provider and cloud partner of Microsoft Azure. The fund also invested in AJ Total’s chilled and frozen warehouse business, content production studio Realies Pictures and golf service platform company Kakao VX earlier this year.
The fund focuses on middle-market high growth companies. Its limited partners include domestic institutional investors such as Korea Development Bank, Teachers’ Pension and the Pension Foundation of the General Assembly of the Presbyterian Church of Korea. (Reporting by Ha-na Suh)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- [이스트소프트는 지금]'알집' 신화로 세운 종합 ICT그룹 '경고등 켜졌다'
- '사랑의열매' OCIO, NH증권 수성 여부 촉각
- 다올운용 라인업 확대 '총력'…해외재간접 펀드 출시
- [스튜어드십코드 모니터]브이아이운용, 현대엘리 표대결서 이사회측 손들었다
- [스튜어드십코드 모니터]다올운용, 삼성전자 이사 후보 '리스크 관리 미흡'
- [성과연동 펀드판매 확산]당국 눈치보며 쉬쉬…법령해석 재확인후 '본격화' 조짐
- [동구바이오제약 신사업 전략]캐시카우만으론 역부족, 벌크업 기반 '오너 보증 차입'
- [LK삼양 뉴비기닝]그룹 오너 구본욱의 변신, 경쟁력 강화만 본다
- [루키 바이오텍 in market]김권 셀비온 대표"경쟁약 넘는 효능, 품목허가 꿈 도전"
- [Policy Radar]바이오시밀러 문턱 낮춘 유럽, 비용·경쟁 판이 바뀐다